Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book is the first of two volumes that offer a comprehensive, up-to-date account of current knowledge regarding high-density lipoprotein (HDL), the changes that occur in HDL under different conditions, the clinical applications of HDL, and means of enhancing HDL functionality. HDL comprises a diverse group of lipoproteins and its composition and metabolism are dynamic. In this volume, the focus is on the changes observed in HDL under different health statuses, with particular attention to the functional and structural correlations of HDL and apolipoprotein A-1. The impacts of a wide…mehr
This book is the first of two volumes that offer a comprehensive, up-to-date account of current knowledge regarding high-density lipoprotein (HDL), the changes that occur in HDL under different conditions, the clinical applications of HDL, and means of enhancing HDL functionality. HDL comprises a diverse group of lipoproteins and its composition and metabolism are dynamic. In this volume, the focus is on the changes observed in HDL under different health statuses, with particular attention to the functional and structural correlations of HDL and apolipoprotein A-1. The impacts of a wide variety of factors on HDL are examined in depth, covering, for example, diet, exercise, smoking, age, diverse diseases, and different forms of environmental pollution. It has long been known that HDL has anti-atherosclerotic and antidiabetic properties, and more recently its anti-aging activities have been recognized. These benefits of HDL are highly dependent on its lipids, proteins, apolipoproteins, and enzymes, and specifically their composition and ratios. In documenting the latest knowledge in this field, this volume will be of interest to both researchers and clinicians.
Kyung-Hyun Cho, Professor, LipoLab, Department of Medical Biotechnology, Yeungnam University, Republic of Korea
Inhaltsangabe
Preface.- Chapter 1. Understanding HDL: overview.- 1-1.HDL and disease.- 1-2.HDL functions and clinical applications.- 1-3.HDL composition : apolipoproteins and enzymes.- 1-4.Maturation of HDL.- 1-5.HDL and blood pressure.- Chapter 2. Change of HDL by life style.- 2-1.Exercise and HDL.- 2-2.Smoking and HDL.- 2-3.Elderly’s HDL.- 2-4.HDL depends on body weight.- 2-5.HDL from obese but healthy subject.- 2-6.HDL and apoA-I in smokers’ breast milk.- 2-7.Breast milk from frequent trans fatty acid consumers.- 2-8.HDL in cord blood from small neonates.- Chapter 3. Change of HDL in various diseases.- 3-1.HDL from patients with myocardial infarction.- 3-2.HDL from patients with female angina pectoris.- 3-3.HDL and metabolic syndrome.- 3-4.HDL from male patients with atrial fibrillation.- 3-5.HDL from female patients with atrial fibrillation.- 3-6.HDL from patients with hemorrhagic fever with renal syndrome.- 3-7.HDL from patients with rheumatoid arthritis.- 3-8.HDL and prehypertension.- Chapter 4. Detriment of HDL by pollutant and its evaluation.- 4-1.Particulate matter and HDL.- 4-2.Phthalate and HDL.- 4-3.Cadmium and HDL.- 4-4.Humidifier Sterilizer and HDL.- 4-5.Detection of dysfunctional HDL by microfluidics.- 4-6.Evaluation of dysfunctional HDL using zebrafish embryo.- Chapter 5. Change of HDL by food ingredient.- 5-1.Fructose and apoA-I.- 5-2.Fructose and impairment of HDL functionality.- 5-3.Artificial sweeteners and apoA-I.- 5-4.Artificial sweeteners (aspartame, saccharin) and HDL.- 5-5.Aldoketohexoses and HDL.- 5-6.Iron and HDL.- 5-7.Trans fat and HDL.- 5-8.Salt and HDL 576 p.- Summary and perspectives.
Chapter 1. Improvement of HDL.- 1-1.Clinical application of HDL: Overview.- 1-2.Regression effect of V156K-apoA-I.- 1-3.Anti-diabetic effect of V156K-apoA-I.- 1-4.Vitamin C and HDL.- 1-5.Growth hormone-1 in HDL.- 1-6.Growth hormone-2 in HDL.- 1-7.Omega-3 and HDL.- Chapter 2. HDL as therapeutic tools.- 2-1.Delivery vehicle for therapeutics : Overview.- 2-2.Gene delivery: adenovirus and V156K-apoA-I.- 2-3.Solubilization of rapamycin and delivery.- 2-4.Solubilization of minoxidil and delivery.- Chapter 3. Enhancement of HDL by policosanol: anti-aging and longevity.- 3-1.Policosanol and HDL functionality.- 3-2.Policosanol and raising HDL in zebrafish.- 3-3.Policosanol and CETP inhibition: human trial 8 weeks.- 3-4.Policosanol and blood pressure lowering: human trial 8 weeks.- 3-5.Policosanol blood pressure lowering human trial for 24 weeks.- 3-6.Policosanol and improvement of aortic stiffness.- 3-7.Policosanol and blood pressure lowering in rat model.- 3-8.Twelve week consumption of policosanol and lowering blood pressure.- 3-9.Publication analysis of policosanol-related studies.- 3-10.Athero-protective effects of policosanol and sugar cane wax acid.- 3-11.Cuban sugarcane wax acids and policosanol improved serum lipid profiles.- Summary and perspectives.- Epilogue.
Preface.- Chapter 1. Understanding HDL: overview.- 1-1.HDL and disease.- 1-2.HDL functions and clinical applications.- 1-3.HDL composition : apolipoproteins and enzymes.- 1-4.Maturation of HDL.- 1-5.HDL and blood pressure.- Chapter 2. Change of HDL by life style.- 2-1.Exercise and HDL.- 2-2.Smoking and HDL.- 2-3.Elderly’s HDL.- 2-4.HDL depends on body weight.- 2-5.HDL from obese but healthy subject.- 2-6.HDL and apoA-I in smokers’ breast milk.- 2-7.Breast milk from frequent trans fatty acid consumers.- 2-8.HDL in cord blood from small neonates.- Chapter 3. Change of HDL in various diseases.- 3-1.HDL from patients with myocardial infarction.- 3-2.HDL from patients with female angina pectoris.- 3-3.HDL and metabolic syndrome.- 3-4.HDL from male patients with atrial fibrillation.- 3-5.HDL from female patients with atrial fibrillation.- 3-6.HDL from patients with hemorrhagic fever with renal syndrome.- 3-7.HDL from patients with rheumatoid arthritis.- 3-8.HDL and prehypertension.- Chapter 4. Detriment of HDL by pollutant and its evaluation.- 4-1.Particulate matter and HDL.- 4-2.Phthalate and HDL.- 4-3.Cadmium and HDL.- 4-4.Humidifier Sterilizer and HDL.- 4-5.Detection of dysfunctional HDL by microfluidics.- 4-6.Evaluation of dysfunctional HDL using zebrafish embryo.- Chapter 5. Change of HDL by food ingredient.- 5-1.Fructose and apoA-I.- 5-2.Fructose and impairment of HDL functionality.- 5-3.Artificial sweeteners and apoA-I.- 5-4.Artificial sweeteners (aspartame, saccharin) and HDL.- 5-5.Aldoketohexoses and HDL.- 5-6.Iron and HDL.- 5-7.Trans fat and HDL.- 5-8.Salt and HDL 576 p.- Summary and perspectives.
Chapter 1. Improvement of HDL.- 1-1.Clinical application of HDL: Overview.- 1-2.Regression effect of V156K-apoA-I.- 1-3.Anti-diabetic effect of V156K-apoA-I.- 1-4.Vitamin C and HDL.- 1-5.Growth hormone-1 in HDL.- 1-6.Growth hormone-2 in HDL.- 1-7.Omega-3 and HDL.- Chapter 2. HDL as therapeutic tools.- 2-1.Delivery vehicle for therapeutics : Overview.- 2-2.Gene delivery: adenovirus and V156K-apoA-I.- 2-3.Solubilization of rapamycin and delivery.- 2-4.Solubilization of minoxidil and delivery.- Chapter 3. Enhancement of HDL by policosanol: anti-aging and longevity.- 3-1.Policosanol and HDL functionality.- 3-2.Policosanol and raising HDL in zebrafish.- 3-3.Policosanol and CETP inhibition: human trial 8 weeks.- 3-4.Policosanol and blood pressure lowering: human trial 8 weeks.- 3-5.Policosanol blood pressure lowering human trial for 24 weeks.- 3-6.Policosanol and improvement of aortic stiffness.- 3-7.Policosanol and blood pressure lowering in rat model.- 3-8.Twelve week consumption of policosanol and lowering blood pressure.- 3-9.Publication analysis of policosanol-related studies.- 3-10.Athero-protective effects of policosanol and sugar cane wax acid.- 3-11.Cuban sugarcane wax acids and policosanol improved serum lipid profiles.- Summary and perspectives.- Epilogue.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
